EMEA-001888-PIP01-15-M02 - paediatric investigation plan
Dengue tetravalent vaccine (live, attenuated)
PIPHuman
Key facts
- Invented name
- Qdenga
- Active Substance
- Dengue tetravalent vaccine (live, attenuated)
- Therapeutic area
- Infections and infestations
- Decision number
- P/0003/2024
- PIP number
- EMEA-001888-PIP01-15-M02
- Pharmaceutical form(s)
- Powder and solvent for solution for injection
- Condition(s) / indication(s)
- Prevention of dengue fever
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Takeda Vaccines, Inc.
E-mail: amy.atwood@takeda.com
Tel. +1 6174 442147- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date